CN115697405A - 用于治疗或预防Th2介导的疾病的含有PD-1激动剂的药物组合物 - Google Patents

用于治疗或预防Th2介导的疾病的含有PD-1激动剂的药物组合物 Download PDF

Info

Publication number
CN115697405A
CN115697405A CN202180037220.XA CN202180037220A CN115697405A CN 115697405 A CN115697405 A CN 115697405A CN 202180037220 A CN202180037220 A CN 202180037220A CN 115697405 A CN115697405 A CN 115697405A
Authority
CN
China
Prior art keywords
ser
cells
thr
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037220.XA
Other languages
English (en)
Chinese (zh)
Inventor
本庶佑
太田明夫
但马正树
镰田春彦
永田谕志
铃木健介
大城裕也
德丸阳介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Pharma Co Ltd
National Institutes of Biomedical Innovation Health and Nutrition
Foundation for Biomedical Research and Innovation at Kobe
Original Assignee
Meiji Seika Pharma Co Ltd
National Institutes of Biomedical Innovation Health and Nutrition
Foundation for Biomedical Research and Innovation at Kobe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd, National Institutes of Biomedical Innovation Health and Nutrition, Foundation for Biomedical Research and Innovation at Kobe filed Critical Meiji Seika Pharma Co Ltd
Publication of CN115697405A publication Critical patent/CN115697405A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180037220.XA 2020-05-25 2021-05-24 用于治疗或预防Th2介导的疾病的含有PD-1激动剂的药物组合物 Pending CN115697405A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020090526 2020-05-25
JP2020-090526 2020-05-25
PCT/JP2021/019676 WO2021241523A1 (ja) 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Publications (1)

Publication Number Publication Date
CN115697405A true CN115697405A (zh) 2023-02-03

Family

ID=78744780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037220.XA Pending CN115697405A (zh) 2020-05-25 2021-05-24 用于治疗或预防Th2介导的疾病的含有PD-1激动剂的药物组合物

Country Status (7)

Country Link
US (1) US20230183347A1 (https=)
EP (1) EP4159235A4 (https=)
JP (1) JP7754455B2 (https=)
KR (1) KR20230015348A (https=)
CN (1) CN115697405A (https=)
TW (1) TWI890796B (https=)
WO (1) WO2021241523A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
KR20240137086A (ko) * 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190270818A1 (en) * 2018-03-02 2019-09-05 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CN107149530A (zh) * 2016-03-04 2017-09-12 吴东 一种洗头装置
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
CN107149680A (zh) 2017-04-27 2017-09-12 中山大学 Pd‑1h激动剂在哮喘治疗中的应用
CN106924718A (zh) 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190270818A1 (en) * 2018-03-02 2019-09-05 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MI-YOUNG SONG等: "Protective effects of Fc-fused PD-L1 on two different animal models of colitis", GUT MICROBIOTA, 10 June 2014 (2014-06-10), pages 1 - 12 *
SANDRA ROSSKOPF等: "PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses", SANDRA ROSSKOPF等, 10 September 2018 (2018-09-10), pages 5 *

Also Published As

Publication number Publication date
US20230183347A1 (en) 2023-06-15
TW202210099A (zh) 2022-03-16
EP4159235A1 (en) 2023-04-05
TWI890796B (zh) 2025-07-21
KR20230015348A (ko) 2023-01-31
EP4159235A4 (en) 2024-07-10
JPWO2021241523A1 (https=) 2021-12-02
JP7754455B2 (ja) 2025-10-15
WO2021241523A1 (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN111526888B (zh) 抗tigit抗体及其作为治疗和诊断的用途
RU2769352C2 (ru) Антитела и полипептиды, направленные против cd127
TWI707950B (zh) 結合分子和使用彼之方法
JP5372500B2 (ja) Ｉｌｔ３結合分子およびその使用
JP6405242B2 (ja) Ｍｉｃａ結合剤
JP6976322B2 (ja) 新規抗ｃｔｌａ４抗体
JP2022501076A (ja) Ｂ７−ｈ３に対するモノクローナル抗体および細胞治療におけるその使用
TW201833326A (zh) Ｃｄ７０結合分子及使用彼之方法
JP2021526012A (ja) Ｃｔｌａ−４を標的とする抗体、その調製方法および使用
JP2018502044A (ja) 抗ｐｄ−１抗体およびその用途
TW200911837A (en) Anti-CD40 monoclonal antibody
CN107073109A (zh) Vista激动剂和拮抗剂抑制或增强体液免疫的用途
CN115697405A (zh) 用于治疗或预防Th2介导的疾病的含有PD-1激动剂的药物组合物
KR20230118913A (ko) 구아닐릴 사이클라제 c (gcc) 항원 결합제의 조성물및 이의 사용 방법
CN116178545B (zh) 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
KR20250059415A (ko) B7-h3 항원-결합 분자
CN111971303B (zh) 抗cd27抗体及其用途
EP4506366A1 (en) Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof
EP4263613A1 (en) Cd40 binding molecules and uses thereof
HK40110611A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
HK40000650A (en) Bcma binding molecules and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination